iRhythm provides innovative and cost-effective diagnostic monitoring solutions that facilitate early diagnosis and treatment decisions, with the goal of ultimately improving patient health outcomes and reducing wasteful healthcare spending. Its flagship product, the Zio?? Patch, is designed to optimize and simplify the diagnosis of cardiac arrhythmias. Zio?? Patch is the smallest, lightest, least conspicuous cardiac arrhythmia diagnostic available and is indicated for up to 14 days of monitoring.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 11/20/12 | $1,500,000 |
California HealthCare Foundation | undisclosed | |
| 04/10/13 | $16,000,000 | Series D |
Kaiser Permanente Ventures New Leaf Venture Partners | undisclosed |
| 05/22/14 | $17,000,000 | Series E |
Novo A/S | undisclosed |
